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Abstract
Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the Parkinson’s disease
(PD) brain. As in the substantia nigra pars compacta, neuronal dropout and Lewy bodies are prominent changes
affecting the locus coeruleus, which is the source of ascending NErgic projections. Despite the major roles of NE
throughout the brain, there has been only minimal exploration of pharmacological intervention with NErgic
neurotransmission. Cognitive operations, “freezing” of gait, tremor, dyskinesia, REM sleep regulation, and other
aspects of brain function are tied into signaling by NE, and there is also evidence that it may have a role in the
neurodegenerative process itself. This article reviews the reported pharmacological experience in PD therapeutics.
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Review
Successful treatment of Parkinson’s disease (PD) with
neurotransmitter replacement has placed dopamine
“center stage” for understanding the pathophysiology of
this disorder. The seminal research of Arvid Carlsson
and other investigators in the 1950s elevated dopamine’s
role from that of a mere metabolic intermediate to the
“star of the show” in PD and other brain disorders.
Neglected by the attention given to dopamine, however,
was the significance of another important CNS neuro-
transmitter, norepinephrine (NE). In nerve terminals
containing the rate-limiting enzyme dopamine-b-hydro-
xylase, NE is formed in the next step in catecholamine
synthesis beyond dopamine. Like dopamine, NE is
involved in a wide range of cognitive, motor, and auto-
nomic functions of the brain. Beyond its roles as a neu-
rotransmitter, the actions of NE are involved in one or
more mechanisms linked to neurodegeneration in the
PD brain [1]. There has been only limited pharmacologi-
cal experience exploring the clinical significance of mod-
ulating NE neurotransmission. This review will cover
the highlights of this therapeutic research experience.
In PD, NE synthesis is greatly decreased throughout the
brain. In several regions, NE content is reduced to less
than half of its usual tissue concentration [2]. CSF
concentration of dopamine-b-hydroxylase (the rate limit-
ing enzyme for NE synthesis) is also diminished [3]. The
loss of NErgic innervation is attributable to the promi-
nent pathology found in the locus coeruleus (LC) [4].
From these paired brainstem structures, ascending pro-
jections arise that are distributed widely to the cerebral
cortex and deeper structures [5]. Long before the signifi-
cance of decreased dopaminergic innervation was under-
stood as a key feature of PD, neuropathologists
recognized that changes in the LC were as extensive as
those affecting neurons in the substantia nigra pars com-
pacta (SNpc) [6]. Beyond the dropout of NErgic neurons
in the LC, the remaining pigmented neurons tend to be
affected with Lewy bodies and Lewy neurites (similar to
findings for dopaminergic neurons in the SNpc). Neuro-
nal degeneration in LC precedes by several years the
development of similar changes in the SNpc [7].
Although the cause(s) in PD for the progressive and rela-
tively selective attack on both the LC and SNpc remains
to be learned, neurons in both brain regions share in
common an intracellular accumulation of neuromelanin
pigment as well as the enzymatic apparatus for catechola-
mine synthesis and catabolism. These factors may confer
vulnerability for neurodegeneration based on oxidative
stress from metabolism of the neurotransmitters or their
auto-oxidation [8].
Research into the etiology of PD has also given con-
sideration to other ways that NE might be involved.
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One intriguing possibility comes from its influence on
inflammatory mechanisms, which have been suspected
to be involved in the common final pathway for the
pathogenesis of PD (regardless of initiating cause) [9]. In
animal experiments, NE inhibits gene expression leading
to pro-inflammatory molecules (especially cytokines)
originating in microglia, astroglia, and endothelial cells
[1]. Other properties associated with NErgic innervation
include the reduction of oxidative stress (by lessening
the formation of nitric oxide and other intracellular
reactive oxygen species), and lessening of both mito-
chondrial membrane depolarization and caspase activa-
tion [10]. As a result, the presence of NE innervation
may protect against neurodegeneration in the SNpc
dopaminergic neurons. Evidence for this possibility
comes from experimental lesioning of the LC, which
adds to the damage of dopaminergic neurons caused by
the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) [11-13]. In contrast, enhancing NE synth-
esis counters the toxicity of MPTP against dopamine-
secreting neurons in experimental Parkinsonism [13,14].
Taken together, the experimental evidence suggests that
a decline in NE synthesis might be a factor in the neu-
rodegenerative disease process of PD.
As with dopamine receptors, adrenoceptors in the
nervous system have a complexity that is conferred by
both their localization and by their differing signal trans-
duction properties. The effects of NE are governed by
an intermingling of receptors with excitatory and inhibi-
tory pre- and post-synpatic functions. NE acts through
both through immediate neurotransmission and also by
long-term potentiation (which facilitates synaptic plasti-
city). It also indirectly enhances glutamate release. The
NErgic output from the LC has a number of physiologi-
cal roles in the brain, including activation of cerebral
cortex for functions such as vigilance, wakefulness, and
circadian rhythms. NE input plays a role in monitoring
of arousal and attentional systems, especially those with
inherent novelty. Attention mechanisms are enhanced
by the influence of NE in the prefrontal cortex, while
short-term memory is facilitated by actions of this neu-
rotransmitter in the hippocampus. Pertinent to neurolo-
gical deficits in PD are additional roles of LC NErgic
innervation with respect to autonomic functions and
regulation of the sleep-wake cycle. NE afferents from
the LC also influence firing patterns of SNpc neurons
and release of striatal dopamine [15].
There has been only limited pharmacological research
with CNS NE to achieve symptomatic therapy of PD. In
several studies, drugs selectively interacting with NE
have offered insight to roles that NE might play in treat-
ing motor, cognitive, and affective features of PD. For
example, clinical manifestations of resting, postural, and
action tremor in PD can be diminished approximately
one-third by the b-adrenoceptor antagonist nadolol [16].
Another b-blocker, propranolol, was claimed to reduce
levodopa-induced dyskinesias in PD patients (and with-
out worsening Parkinsonism) [17]. Levodopa-induced
dyskinesias have also been diminished by other interac-
tions with NE neurotransmission. For example, treat-
ment with the a2-adrenergic receptor antagonists
idaxozan [18] and fipemazole [19] reduced involuntary
movements without a reduction in the anti-Parkinsonian
benefits of levodopa.
Other motor features of PD and its therapeutics have
been investigated by means of a drug that can selectively
enhance NE production in the brain. The L-threo form
of dihydroxyphenylserine (L-DOPS, or droxidopa) is an
unnatural amino acid developed for pharmaceutical pur-
poses. Although lacking any pharmacological effects by
itself, L-DOPS is capable of direct conversion to NE by
L-aromatic amino acid decarboxylase (the same enzyme
that converts levodopa to dopamine). L-DOPS has been
extensively used to treat orthostatic hypotension by
increasing peripheral NE synthesis [20]. If the decarbox-
ylase inhibitors carbidopa or benserazide are co-admi-
nistered with L-DOPS, then most of this NE precursor
is blocked from metabolism outside of the CNS. Like
levodopa, L-DOPS crosses the blood-brain barrier by a
facilitated amino acid transport mechanism.
In Japan, where the drug has been marketed since
1991, L-DOPS underwent investigation to investigate
the role of NE in advanced PD. In a multicenter pla-
cebo-controlled study, some patients experiencing freez-
ing of gait and retropulsive imbalance exhibited marked
clinical improvements from L-DOPS [21]. Following
these studies, there have been no further randomized
clinical trials, and so the question of L-DOPS effective-
ness in the problems of advanced PD awaits further
study. Even when L-DOPS is co-administered with a
decarboxylase inhibitor, recent clinical experience indi-
cates that this drug can improve symptomatic features
of postural hypotension experienced by PD patients [20].
Beyond its effects on motor aspects of PD, the role of
NE in cognitive functions has been of particular interest
for pharmacological interventions. Since the LC provides
extensive projections to frontal cortex, several investiga-
tors have hypothesized that modulating NErgic neuro-
transmission might help with the various types of
cognitive deficits found in PD. In one small-scale study,
administering a selective NErgic a-1 agonist was asso-
ciated with improved performance for attentional defi-
cits in nondemented PD patients [22]. Another
investigation found that treatment with the a-2 adreno-
ceptor agonist clonidine (which acts to decrease NE
release in the brain) led to improved spatial working
performance [23]. The NE re-uptake inhibitor atomoxe-
tine showed a trend for improving several frontal lobe
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measures of cognitive performance in a small open-label
study of non-demented PD patients [24]. Apart from
these few clinical investigations, the role of NE in the
range of PD-associated cognitive impairments [25] has
not been explored.
The increased risk for occurrence of depression affecting
PD patients has been associated with neurochemical
changes that include the LC projections to limbic struc-
tures [26]. As a result, the reduction in NE neurotransmis-
sion may offer a pharmacological target. This possibility
was explored in a clinical trial testing whether reboxetine,
a selective NE re-uptake inhibitor, could offer improve-
ment for a major depressive episode in PD patients. With
this drug, the outcome was quite striking, as shown by
improvements in Hamilton Depression Scale scores that
were comparable to the best that serotonin-selective reup-
take inhibitors achieve in treating depression for non-PD
populations [27]. During this clinical trial, no changes
occurred in ratings of Parkinsonian severity.
The studies described above constitute the sum of
investigations in PD with respect to NE and the various
deficits associated with this disorder. Given the impor-
tance of NErgic innervation in the brain and its major
loss in PD, it would seem that this neglected neuro-
transmitter deserves greater pharmacological attention.
Dopaminergic therapy of PD has greatly changed the
options for achieving a lasting control of PD disabilities.
Despite this, there are many continuing challenges for
the further development of PD therapeutics (Table 1).
Some of these unmet needs may be related to the var-
ious roles of NE in the brain. The studies described
above, however meager, suggest that augmenting or
blocking NE neurotransmission has the potential to
improve several motor and non-motor problems of PD.
Furthermore, NE’s possible role at protecting against the
progression of PD awaits study. One opportunity to
explore the role of NErgic functions in the brain and
systemically is with the NE precursor L-DOPS, which
offers a selective pharmacological probe for augmenting
NE neurotransmission. Using L-DOPS, the author is
planning to initiate clinical trials to study the effects of
increasing brain NE for treating cognitive impairments
and freezing of gait in PD patients.
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